Recent progresses in Cardio-Kidney-Metabolic diseases, which affect >40% world population, make Pharma investing heavily on new CKM candidates. But they lack tools to identify/stratify early kidney injury cases and lack surrogate markers to monitor nephroprotection. To help Pharma unlock the big market, Quant Biomarkers is developing the RenoRisk biomarker panel that originate from and can detect the earliest pathology of kidney injury, enabling a 3-6yr earlier reversible treatment time window.